Shows
Morning AirAnointing of the Sick/ 4 Decisions for a Healthy Marriage7/8/24 7am CT Hour - Fr. John Gordon/ Carol and Pete Tomaselli John, Glen and Sarah chat about Hurricane Beryl, Democrats response to President Biden, and NEC Pilgrimage update. Fr. John talks about Pope Francis' July prayer intention on the anointing of the sick. Carol and Pete go over the 4 decisions you can make that will keep your marriage healthy.
2024-07-0850 min_1400x1400.jpg)
The Pharm So Hard Podcast: An Emergency Medicine and Hospital Pharmacy PodcastPut It in Reverse Terry! Fixed-Dosed Four Factor Prothrombin Complex Concentrate (PCC) for Vitamin K Antagonist ReversalReferences Kcentra (prothrombin complex concentrate [Human]) [package insert]. Kankakee, IL: CSL Behring LLC; 2013. Tomaselli, Gordon F., et al. “2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.” Journal of the American College of […]
The post Episode 43: Put It in Reverse Terry! Fixed-Dosed Kcentra for Vitamin K Antagonist Reversal appeared first on The Pharm So Hard Podcast.
2021-07-0910 min
Audio Medica News - Medical News InterviewsCARDIOVASCULAR: Torcetrapib in Patients at High Risk for Coronary Events: ILLUMINATE Trial Latest ResultsAudio Journal of Cardiovascular Medicine, November 6th, 2007
Reporting from: American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
Torcetrapib in Patients at High Risk for Coronary Events: ILLUMINATE Trial Latest Results
PHILIP BARTER, Heart Research Institute, Sydney, Australia
COMMENT: GORDON TOMASELLI, Johns Hopkins University, Baltmimore
REFERENCE: Late Breaking Clinical Trials Session 2
A randomized double-blind study involving over 15,000 patients at high cardiovascular risk which looked at the new agent torcetrapib (an inhibitor of cholesteryl ester transfer protein, CETP) resulted in higher mortality in the experimental arm. The study compared torcetrapib plus atorvastatin with atorvatstin alone. Inhibition of CETP increases HDL levels...
2007-11-0607 minAudio Medica News - Medical News InterviewsCARDIOVASCULAR: Rosuvastatin: No Significant Benefit for Older Patients with Systolic Heart Failure: CORONA Study ResultsAudio Journal of Cardiovascular Medicine, November 6th, 2007
Reporting from: American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
Rosuvastatin: No Significant Benefit for Older Patients with Systolic Heart Failure: CORONA Study Results
AKE HJALMARSON, Sahlgrenska University, Göteborg
COMMENT: GORDON TOMASELLI, Johns Hopkins University, Baltmimore
REFERENCE: Late Breaking Clinical Trials Session 2 & N Engl J Med 2007;357
The lipid lowering agent rosuvastatin did not bring a significant benefit to older patients with systolic heart failure, according to the findings of the CORONA study released at the American Heart Association sessions in Orlando. Ake Hjalmarson talked with Peter Goodwin about the implications this h...
2007-11-0607 min
Cardiovascular – AudioMedica.comTorcetrapib in Patients at High Risk for Coronary Events: ILLUMINATE Trial Latest Results
Philip Barter
Gordon Tomaselli
REFERENCE: Late Breaking Clinical Trials, Session 2, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida N Engl J Med 2007;357
PHILIP BARTER, Heart Research Institute, Sydney, Australia
COMMENT: GORDON TOMASELLI, Johns Hopkins University, Baltimore…
2007-11-0600 minCardiovascular – AudioMedica.comRosuvastatin: No Significant Benefit for Older Patients with Systolic Heart Failure: CORONA Study Results
Ake Hjalmarson
Gordon Tomaselli
REFERENCE: Late Breaking Clinical Trials, Session 2, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida N Engl J Med 2007;357
AKE HJALMARSON, Sahlgrenska University, Göteborg
COMMENT: GORDON TOMASELLI, Johns Hopkins University, Baltimore
The lipid …
2007-11-0600 minAudio Medica News - Medical News InterviewsCARDIOVASCULAR: TRITON-TIMI 38 Prasugrel Or Clopidogrel In Percutaneous Intevention?Audio Journal of Cardiovascular Medicine, November 5th, 2007
Reporting from: American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
TRITON-TIMI 38 Prasugrel Or Clopidogrel In Percutaneous Intevention?
GORDON TOMASELLI, Johns Hopkins University, Baltimore
COMMENT: DANIEL JONES, President, American Heart Association, University of Mississippi, Jackson
REFERENCE: Late Breaking Clinical Trials 1, AHA 2007
A potential new option for patients with acute coronary syndromes receiving coronary intervention has emerged following a report on the comparison of prasugrel, a new anti-platelet agent, with clopidogrel. Elliott Antman from Brigham and Women’s Hospital in Boston gave the American Heart Association his findings and recommendations about when and in wh...
2007-11-0505 minCardiovascular – AudioMedica.comTRITON-TIMI 38 Prasugrel Or Clopidogrel In Percutaneous Intevention?
Gordon Tomaselli
Daniel Jones
REFERENCE: Late Breaking Clinical Trials 1, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
GORDON TOMASELLI, Johns Hopkins University, Baltimore
COMMENT: DANIEL JONES, President, American Heart Association, University of Mississippi, Jackson
A potential new …
2007-11-0500 minAHA 2005 – AudioMedica.comCOMMENTSGordon TomaselliGordon Tomaselli commented on Milton Packer’s findings at the Dallas meeting of the American Heart Association.[audio:https://www.audiomedica.com/podcasting/aha2005/Gordon_Tomaselli-Comment_Packer.mp3]Click here for all the interviews from AHA 2005…
2005-11-1600 minAHA 2005 – AudioMedica.comCOMMENTSGordon TomaselliGordon Tomaselli, Johns Hopkins School of MedicineGordon Tomaselli commented on Volker Schächinger’s findings at the Dallas meeting of the American Heart Association.[audio:https://www.audiomedica.com/podcasting/aha2005/Tomaselli_Schachinger.mp3]Click here for all the interviews from AHA 2005…
2005-11-1600 min